Epidemiological studies have shown that the risk of venous thromboembolic events (VTE) due to the use of combined oral contraceptives (COCs) containing drospirenone is greater than when taking COCs containing levonorgestrel (so-called second generation COCs). The data also suggest that the VTE risk associated with COCs containing drospirenone could be similar to that of COCs containing desogestrel and gestodene (so-called third generation COCs)."

risk informatrisk information - full text (available in German only)